급성위장염 소아환자에서 ondansetron 경구요법 시행 후정맥내 수액요법 빈도 및 응급실 체류시간의 변화
Changes in intravenous hydration frequency and emergency department length of stay after implementation of oral ondansetron therapy in children with dehydration due to acute gastroenteritis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Oral ondansetron is a safe and effective antiemetic drug to facilitate oral rehydration therapy in acute gastroenteritis (AGE) with mild dehydration. We investigated the effect of oral ondansetron therapy on intravenous (IV) hydration frequency and emergency department length of stay (EDLOS) in dehydrated children with AGE. Methods: We reviewed 15,813 children aged 12-60 months with primary diagnosis of AGE who visited a tertiary care university-affiliated hospital emergency department. The enrolled children were divided into the pre- (from January 2009 to June 2011) and post- (from January 2016 to June 2018) ondansetron groups according to the implementation of oral ondansetron therapy in the emergency department. As primary outcomes, IV hydration frequency, EDLOS, and hospitalization rate were compared between the 2 groups. As secondary outcomes, EDLOS and hospitalization rate were compared between the children in the post-ondansetron group who underwent the therapy, and those who did not. Results: Of 7,990 enrolled children, 3,300 (41.3%) were designated as the post-ondansetron group, and among them 1,093 (33.1%) underwent oral ondansetron therapy. This group showed a lower IV hydration frequency, a shorter median EDLOS compared to the other group (55.8% vs. 61.9%, P < 0.001; 175.0 vs. 223.0 minutes, P < 0.001, respectively), and a higher hospitalization rate (9.9% vs. 7.9%, P < 0.001). The children in the post-ondansetron group who underwent the therapy showed a shorter median EDLOS and a lower hospitalization rate compared to those who did not (142.0 vs. 205.0 minutes, P < 0.001; 2.9% vs. 13.4%, P < 0.001, respectively). Conclusion: Oral ondansetron therapy may reduce IV hydration frequency and EDLOS in dehydrated children with AGE, and can be considered in those having severe vomiting.
Abstract
Purpose: Oral ondansetron is a safe and effective antiemetic drug to facilitate oral rehydration therapy in acute gastroenteritis (AGE) with mild dehydration. We investigated the effect of oral ondansetron therapy on intravenous (IV) hydration frequency and emergency department length of stay (EDLOS) in dehydrated children with AGE. Methods: We reviewed 15,813 children aged 12-60 months with primary diagnosis of AGE who visited a tertiary care university-affiliated hospital emergency department. The enrolled children were divided into the pre- (from January 2009 to June 2011) and post- (from January 2016 to June 2018) ondansetron groups according to the implementation of oral ondansetron therapy in the emergency department. As primary outcomes, IV hydration frequency, EDLOS, and hospitalization rate were compared between the 2 groups. As secondary outcomes, EDLOS and hospitalization rate were compared between the children in the post-ondansetron group who underwent the therapy, and those who did not. Results: Of 7,990 enrolled children, 3,300 (41.3%) were designated as the post-ondansetron group, and among them 1,093 (33.1%) underwent oral ondansetron therapy. This group showed a lower IV hydration frequency, a shorter median EDLOS compared to the other group (55.8% vs. 61.9%, P < 0.001; 175.0 vs. 223.0 minutes, P < 0.001, respectively), and a higher hospitalization rate (9.9% vs. 7.9%, P < 0.001). The children in the post-ondansetron group who underwent the therapy showed a shorter median EDLOS and a lower hospitalization rate compared to those who did not (142.0 vs. 205.0 minutes, P < 0.001; 2.9% vs. 13.4%, P < 0.001, respectively). Conclusion: Oral ondansetron therapy may reduce IV hydration frequency and EDLOS in dehydrated children with AGE, and can be considered in those having severe vomiting.
참고문헌 (14)
- GBD 2015 Mortality and Causes of Death Collaborators, "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015", Lancet, 388, pp.1459~1544 (2016)
- American Academy of Pediatrics, "Practice parameter: the management of acute gastroenteritis in young children", Pediatrics, 97, pp.424~435 (1996)
- Ozuah PO, "Oral rehydration, emergency physicians, and practice parameters: a national survey", Pediatrics, 109, pp.259~261 (2002)
- Sandhu BK, "A multicentre study on behalf of the European Society of Paediatric Gastroenterology and Nutrition Working Group on Acute Diarrhoea. Early feeding in childhood gastroenteritis", J Pediatr Gastroenterol Nutr, 24, pp.522~527 (1997)
- Freedman SB, "Oral ondansetron for gastroenteritis in a pediatric emergency department", N Engl J Med, 354, pp.1698~1705 (2006)
- Freedman SB, "Timeseries analysis of ondansetron use in pediatric gastroenteritis", J Pediatr Gastroenterol Nutr, 54, pp.381~386 (2012)
- Marchetti F, "Oral ondansetron versus domperidone for acute gastroenteritis in pediatric emergency departments:multicenter double blind randomized controlled trial", PLoS One, 11, pp.e0165441~ (2016)
- Reeves JJ, "Ondansetron decreases vomiting associated with acute gastroenteritis: a randomized, controlled trial", Pediatrics, 109, pp.e62~ (2002)
- Kersten H, "Oral ondansetron decreases the need for intravenous fluids in children with gastroenteritis", J Pediatr, 149, pp.726~ (2006)
- Sturm JJ, "Ondansetron use in the pediatric emergency room for diagnoses other than acute gastroenteritis", Pediatr Emerg Care, 28, pp.247~250 (2012)
- Freedman SB, "Impact of increasing ondansetron use on clinical outcomes in children with gastroenteritis", JAMA Pediatr, 168, pp.321~329 (2014)
- Rutman L, "Clinical pathway produces sustained improvement in acute gastroenteritis care", Pediatrics, 140, pp.e20164310~ (2017)
- Bender BJ, "Oral rehydration therapy:is anyone drinking?", Pediatr Emerg Care, 23, pp.624~626 (2007)
- Chow CM, "Acute gastroenteritis: from guidelines to real life", Clin Exp Gastroenterol, 3, pp.97~112 (2010)